Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 552 of 6351
-
New drug combo aims to fight aggressive lung cancer
Disease control Recruiting nowSmall cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Weekly pill could help shed pounds in obesity trial
Disease control CompletedThe aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
Phase 2 • Sponsor: Verdiva Bio Dev Limited • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New 24-Valent vaccine aims to shield children from more pneumonia strains
Vaccine Recruiting nowA Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenici…
Phase 2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:06 UTC
-
New shot could replace aspirin to stop clots after knee surgery
Disease control Recruiting nowThis study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a bispecific antibody wipe out stubborn CLL cells?
Disease control Recruiting nowThe goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SL…
Phase 1/2 • Sponsor: Inhye Ahn • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug combo aims to wipe out lung cancer before surgery
Disease control Recruiting nowThe study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
Phase 2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Blood test could spare thousands from unnecessary breast cancer scares
Diagnosis By invitation onlyThe project aims to investigate whether breast cancer screening can be improved using blood tests, thereby reducing the number of unnecessary clinical mammographies. The Danish breast cancer screening program was implemented in 2007, and currently, all women aged 50-69 are invite…
Sponsor: Vejle Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Brain pacemaker showdown: which target best eases Parkinson's symptoms?
Disease control Not yet recruitingThe primary objective of this prospective, multicenter, double-blind, randomized, crossover clinical trial is to evaluate whether Subthalamic Nucleus-Deep Brain Stimulation (STN-DBS) is more effective than Globus Pallidus Internus-Deep Brain Stimulation (GPi-DBS) in improving mot…
Sponsor: Zhang Jianguo • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for advanced lung cancer: drug cocktails under trial
Disease control Recruiting nowThe purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New obesity drug tirzepatide aims to shed pounds and prevent diabetes
Disease control Recruiting nowThe purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Eligible participants must be registered p…
Phase 4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 08:00 UTC
-
Could a simple Self-Swap replace the speculum for cervical cancer screening?
Diagnosis Recruiting nowThis clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections …
Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
New radiation strategy aims to stop ewing sarcoma from coming back
Disease control Recruiting nowThis clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shri…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill shows promise for severe eczema sufferers
Disease control OngoingThis phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity a…
Phase 2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could this antibody be the key to slowing Parkinson's?
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for tough breast cancer: drug cocktail trial launches
Disease control Recruiting now* This study was an open, multicenter phase II clinical trial that enrolled 118 patients with HR+/HER2- with recurrent or progressive advanced breast cancer treated with CDK4/6 inhibitors; * The study adopted the Simon phase 2 design, and all 20 eligible patients were treated wit…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Single-Day light and sound therapy could replace surgery for common skin cancer
Disease control Recruiting nowEvaluation of a therapeutic protocol based on the combination of photodynamic therapy and sonodynamic therapy, referred to as sonophotodynamic therapy. Since this new protocol is applied in a single day, it is called the single-visit Sono-PDT protocol. This protocol will be used …
Phase 3 • Sponsor: University of Sao Paulo • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cocktail of three drugs shows promise for tough kidney cancers
Disease control Recruiting nowThe goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation renal cell carcinoma (tRCC). The name of the study d…
Phase 2 • Sponsor: Stephanie Berg • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New camera could save hearts: OCTAVE trial tests smarter stent placement
Disease control By invitation onlyThe purpose is to investigate if a strategy of routine OCT based diagnosis and guidance of PCI improves clinical outcomes compared with a standard strategy of guidance by angiography in patients presenting with ACS
Sponsor: Aarhus University Hospital Skejby • Aim: Disease control
Last updated Sep 10, 2026 08:00 UTC
-
New drug targets Life-Threatening immune storm in rheumatic patients
Disease control Recruiting nowA study designed to evaluate the efficacy, safety, immunogenicity, PK, and PD characteristics of Plonmarlimab in patients with relapsed/refractory rheumatic and immunologic disease-associated MAS, and to explore biomarkers related to the efficacy of Plonmarlimab.
Phase 3 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental ‘In vivo’ CAR-T therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis is a single-arm, open-label, single-center, dose-escalation Phase I platform study designed to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of an in vivo CAR-T therapy (V001 Injection, targeting BCMA, GPRC5D, DLL3,FcRH5, etc…
Early phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC